Ajanta Pharma Ltd (AJANTPHARM) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Ajanta Pharma Ltd on NSE and BSE, with an AI summary of each filing.
Pls find enclosed Earnings Call Written Transcript
Transcript · 04 Nov 2026, 5:09 pm
Pls find enclosed Audio recording of Earnings Call
Audio / Video · 30 Oct 2026, 11:15 pm
Ajanta Pharma Releases Q2 FY27 Earnings Call Audio Recording Ajanta Pharma Limited informed exchanges that it has uploaded the audio recording of its earnings conference call held on 30th Oct'26 at 4:00 PM to discuss financial results. The recording is publicly accessible on the company's official website under the investor relations section. A written transcript of the call will be submitted in due course.
Ajanta Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 30 Oct 2026, 6:32 pm
Ajanta Pharma Reports Robust Q2 FY'27 Results with PAT Surging 49% YoY Ajanta Pharma posted a strong Q2 FY'27 performance, with consolidated revenue rising 33% YoY to Rs. 1,794 cr. and net profit surging 49% YoY to Rs. 388 cr. Adjusted EBITDA expanded 47% YoY to Rs. 543 cr., achieving a 30% margin. Growth was driven by Branded Generics rising 23% YoY to Rs. 1,182 cr., US Generics surging 41% YoY to Rs. 484 cr., and Africa Institution jumping 259% YoY. For H1 FY'27, revenue reached Rs. 3,420 cr. with healthy ROCE at 41% and ROE at 31%.
Pls find enclosed results for the quarter ended 30.09.2026.
Financial Result · 30 Oct 2026, 6:29 pm
Ajanta Pharma Reports Robust Q2 FY27 With PAT Up 49% YoY Ajanta Pharma reported strong Q2 FY27 consolidated revenue from operations of Rs. 1,794 cr., up 33% YoY. Adjusted EBITDA grew 47% YoY to Rs. 543 cr. with margins at 30%, while net profit rose 49% YoY to Rs. 388 cr. (PAT margin at 22%). Branded generics revenue grew 23% YoY to Rs. 1,182 cr., supported by India (+16%), Asia (+18%), and Africa (+41%). US Generics posted 41% YoY growth to Rs. 484 cr. For H1 FY27, revenue reached Rs. 3,420 cr. (+29% YoY) with PAT of Rs. 722 cr. (+40% YoY).
Pls find enclosed Financial Results for the quarter ended 30.09.2026.
Outcome · 30 Oct 2026, 6:25 pm
Ajanta Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore) ■ Revenue: 1,794 (+32.5% YoY | +10.3% QoQ) ■ EBITDA: 548 (+67.0% YoY | +29.3% QoQ) ■ EBITDA Margin (%): 30.5 (+630 bps YoY | +447 bps QoQ) ■ PAT: 388 (+49.2% YoY | +16.1% QoQ) ■ EPS (INR): 31.0 (+49.0% YoY | +16.1% QoQ)
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 19, 2026 for Aayush Agrawal, trustee ....
Encumbered Shares - Invocation / Release · 21 Oct 2026, 5:40 pm
Ajanta Pharma Promoter Pledges Additional Shares Due to Margin Call Aayush Agrawal (Trustee, Aayush Agrawal Trust), promoter of Ajanta Pharma Limited, pledged 30,000 equity shares (0.02% of total share capital) on 15th Oct'26 in favor of CTL Trusteeship Limited. The pledge creation was triggered by a top-up margin call resulting from a reduction in the share price. Following this transaction, the trust's encumbered shareholding increased from 1,21,02,386 shares (9.69%) to 1,21,32,386 shares (9.71% of total share capital), while total trust holding remains at 1,41,12,924 shares (11.29%).
Pls find enclosed Earnings Conference Call Intimation.
Intimation · 30 Oct 2026, 4:00 pm
Ajanta Pharma Schedules Q2 FY27 Earnings Call for 30th Oct'26 Ajanta Pharma Limited will release its unaudited financial results for Q2 FY27 on 30th Oct'26. Following the Board meeting, the company will host an earnings conference call at 16:00 hrs IST (06:30 hrs US ET) on the same day to discuss financial performance and address investor questions. Audio playback of the call will be accessible on the company's website 120 minutes after completion, alongside a call transcript. Universal dial-in numbers include +91 22 6280 1542 and +91 22 7115 8372.
AJANTA PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 30-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 30 Oct 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 30 Oct 2026, 5:30 am
Ajanta Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2026 ,inter alia, to consider and approve Unaudited consolidated and standalone ....
Intimation · 30 Oct 2026, 5:30 am
Ajanta Pharma Schedules Board Meeting for Q2 and H1 Earnings Ajanta Pharma Limited informed stock exchanges that its Board of Directors will meet on 30th Oct'26. The board will consider and approve the unaudited standalone and consolidated financial results for the second quarter and half year ended 30th Sep'26, pursuant to Regulation 29 of SEBI Listing Regulations.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 06, 2026 for Aayush Agrawal, trustee ....
Encumbered Shares - Invocation / Release · 06 Oct 2026, 4:02 pm
Ajanta Pharma Promoter Pledges Additional Shares for NCD Issuance Ajanta Pharma promoter entity, Aayush Agrawal (Trustee of Aayush Agrawal Trust), created a pledge on 4,60,000 equity shares (0.37% of total share capital) on 28th Sep'26 in favor of CTL Trusteeship Ltd to back an NCD issuance. Following this transaction, the trust's total encumbered holding increased from 1,16,42,386 shares (9.32% of total share capital) to 1,21,02,386 shares (9.69% of total share capital), against its overall holding of 1,41,12,924 equity shares (11.29% stake).
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CTL Trusteeship Ltd
Acquisition/ Disposal of Shares · 01 Oct 2026, 6:40 pm
CTL Trusteeship Discloses Additional Share Pledge in Ajanta Pharma CTL Trusteeship Limited disclosed an additional pledge of 26,21,067 equity shares (2.10% voting capital) of Ajanta Pharma Ltd, executed across 24th Jul'26 and 28th Sep'26. Consequently, its total pledged holding increased from 5.31% (66,32,651 shares) to 7.41% (92,53,718 shares), while total encumbered shares stand at 13.53% (1,63,32,924 shares). The pledge secures unlisted, non-convertible debentures issued/to be issued by Lenexis Foodworks Private Limited (up to ₹3,373 crore) and Inspira Realty 2 Private Limited (up to ₹500 crore) in favour of CTL Trusteeship as common security trustee.
Pls find enclosed herewith Sustainability Report for FY 2026.
Others (Uncategorized) · 30 Sept 2026, 2:57 pm
Ajanta Pharma Releases FY'26 Sustainability Report Highlighting Decarbonisation and Capacity Expansion Ajanta Pharma submitted its voluntary FY'26 Sustainability Report, aligned with GRI Standards. Operational highlights include revenue rising 17% YoY to ₹5,453 cr., supported by tripling liquid formulation capacity at Pithampur to 18mn bottles annually. On ESG metrics, Scope 1 emissions fell 47% to 3,364 tCO2e, while installed solar capacity reached 16.6 MW, meeting 34% of energy needs. R&D investments reached ₹252 cr. (4.6% of revenue), delivering 53 product launches globally. Zero fatalities, zero product recalls, and zero data breaches were reported during the fiscal.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 28, 2026 for Aayush Agrawal, ....
Encumbered Shares - Invocation / Release · 28 Sept 2026, 2:53 pm
Ajanta Pharma Promoter Aayush Agrawal Releases Pledge on 98,185 Shares Ajanta Pharma promoter entity, Aayush Agrawal (Trustee of Aayush Agrawal Trust), released a pledge on 98,185 equity shares following loan repayments to Aditya Birla Capital Ltd. The releases occurred across three tranches: 55,500 shares (0.04%) on 21st Sep'26, 18,518 shares (0.01%) on 22nd Sep'26, and 24,167 shares (0.02%) on 23rd Sep'26. Consequently, the trust's encumbered holding decreased from 1,17,40,571 shares (9.40% of total share capital) to 1,16,42,386 shares (9.32%), out of its total holding of 1,41,12,924 shares (11.29%).
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 18, 2026 for Aayush Agrawal, ....
Encumbered Shares - Invocation / Release · 18 Sept 2026, 10:01 pm
Ajanta Pharma Promoter Releases Pledge on 17.36 Lakh Shares Ajanta Pharma Limited promoter entity, Aayush Agrawal (Trustee of Aayush Agrawal Trust), disclosed the release of pledge on 17,36,353 equity shares following loan repayments. The releases occurred on 11th Sep'26 and 15th Sep'26 across multiple lenders, including JM Credit Ltd (2,01,674 shares; 0.16%), Standard Chartered Capital Ltd (2,19,865 shares; 0.18%), Bajaj Finance Ltd (9,25,926 shares; 0.74%), and Aditya Birla Capital Ltd (3,88,888 shares across two tranches; 0.31%). Post-release, the promoter trust's encumbered holding decreased to 1,17,40,571 shares (9.40% of total share capital).
Pls find enclosed Intimation w.r.t Participation in Investor Conference.
Others (Uncategorized) · 31 Aug 2026, 5:14 pm
Ajanta Pharma Announces September Investor Conference Schedule Ajanta Pharma has announced its participation in upcoming investor conferences. Management will attend the Jefferies India Forum for one-on-one meetings on 16th Sep'26 in New Delhi. Subsequently, the company will participate in the PL Capital Mid & Small Cap Conference 2026 on 28th Sep'26 at Trident, BKC. Discussions will be based on publicly available information. The schedule is subject to change.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 27, 2026 for Aayush Agrawal, trustee ....
Encumbered Shares - Invocation / Release · 27 Aug 2026, 9:01 pm
Ajanta Pharma: Promoter Aayush Agrawal Trust Adjusts Share Pledge Promoter Aayush Agrawal Trust disclosed transactions involving Ajanta Pharma shares on 24th Aug'26. The trust released a pledge on 976,000 shares (0.78% of total) held with RBL Bank Ltd following loan repayment. Concurrently, a new pledge was created on 920,000 shares (0.74%) with 360 One Prime Ltd for additional security. This results in a net decrease of 56,000 pledged shares, reducing the trust's total encumbered holding from 10.83% to 10.79% of the company's share capital.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 19, 2026 for Ravi Agrawal, trustee ....
Encumbered Shares - Invocation / Release · 19 Aug 2026, 11:11 pm
Ajanta Pharma: Promoter Releases Pledge on Shares Promoter Ravi Agrawal (as trustee of Ravi Agrawal Trust) released a pledge on 6,910 equity shares of Ajanta Pharma on 14th Aug'26, citing "Excess Pledge" as the reason. The release was made from Aditya Birla Capital Limited. This action reduces the total number of pledged shares held by the trust to 1,473,390, which represents 1.18% of the company's total share capital. The disclosure was filed with exchanges on 19th Aug'26.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 14, 2026 for Ravi Agrawal, trustee ....
Encumbered Shares - Invocation / Release · 14 Aug 2026, 6:20 pm
Ajanta Pharma Promoter Releases Pledge on 54,796 Shares Promoter Ravi Agrawal, as trustee for the Ravi Agrawal Trust, released a pledge on 54,796 equity shares of Ajanta Pharma between 06-Aug-26 and 12-Aug-26. The release, attributed to an "Excess Pledge," was executed in five separate tranches. Post-release, the trust's total encumbered shares decreased from 1.23% to 1.18% of the company's total share capital. The remaining pledged holding for the trust stands at 1,480,300 shares as of 12-Aug-26. The disclosure was filed with exchanges on 14-Aug-26.
Pls find enclosed Intimation w.r.t participation in Investor Conference
Others (Uncategorized) · 05 Aug 2026, 10:25 pm
Ajanta Pharma Schedules August 2026 Investor Conferences Ajanta Pharma has announced its participation in two upcoming investor conferences in Aug'26. The company will attend the Nuvama India Conference 2026 (Singapore & Hong Kong Edition) for one-on-one meetings from 11th to 13th Aug'26. This will be followed by participation in the Motilal Annual Global Conference on 18th Aug'26 at the Grand Hyatt, Santacruz. The schedule is subject to change, and discussions will be based on publicly available information.
Pls find enclosed herewith Earning Call Transcript
Transcript · 03 Aug 2026, 9:57 pm
Pls find enclosed Audio Recording of Earnings Call
Audio / Video · 30 Jul 2026, 11:08 pm
Ajanta Pharma Earnings Call Audio Recording Published Ajanta Pharma has released the audio recording of its earnings call held on 30th Jul'26 at 4:15 p.m. The recording covers the company's financial and operational performance for Q1 FY27. It has been uploaded to the company's website in compliance with SEBI's Regulation 30. A written transcript of the call is expected to be submitted in due course. The BSE scrip code is 532331 and the NSE scrip code is AJANTPHARM EQ.
Pls find enclosed ESOP Allotment
Others (Uncategorized) · 30 Jul 2026, 8:21 pm
Ajanta Pharma Allots Equity Shares Upon Exercise of Options Ajanta Pharma's Nomination & Remuneration Committee on 30 Jul'26 allotted 23,400 fully paid-up equity shares of Rs. 2/- each upon the exercise of employee stock options. Consequent to this allotment, the company's paid-up share capital has increased to Rs. 24,99,18,048, comprising 12,49,59,024 equity shares. The newly issued shares will be listed on the exchanges in due course. This action results in a minor equity dilution for existing shareholders.
PFA record date intimation
Dividend · 30 Jul 2026, 8:13 pm
Ajanta Pharma Announces Record Date for First Interim Dividend Ajanta Pharma has fixed Wednesday, 5th Aug'26, as the record date for determining shareholder eligibility for its first interim dividend. The company has not announced a book closure period for this purpose. The dividend payout details, including the amount per share, were not specified in this intimation. This action is pursuant to SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015. The stock trades under the symbols AJANTPHARM on the NSE and 532331 on the BSE.
PFA Dividend Intimation
Dividend · 30 Jul 2026, 8:12 pm
Ajanta Pharma Q1 FY27 Revenue Up 25% YoY, Declares Rs. 32 Interim Dividend Ajanta Pharma reported strong Q1 FY27 results with consolidated revenue at Rs. 1,626 cr, up 25% YoY, and PAT at Rs. 334 cr, a 31% YoY increase. Growth was driven by US Generics (+57%), Africa Institution (+83%), and India (+24%), while Asia sales declined 16%. Adjusted EBITDA grew 21% to Rs. 454 cr with a margin of 28%. The Board declared a Rs. 32 per share interim dividend (Rs. 400 cr total payout), with a record date of 5th Aug’26 and payment on/after 18th Aug’26.